FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068240849> ?p ?o ?g. }

• W2068240849 endingPage "2398" @default.
• W2068240849 startingPage "2393" @default.
• W2068240849 abstract "The efficacy of antithymocyte globulin (ATG) induction in the therapy of immunologically low- and high-risk patients after heart transplantation is not known.All patients who received ATG induction from January 2000 through January 2010 were divided into two groups based on the risk of rejection. A higher-risk group (age younger than 60 years, multiparous females, African Americans, panel-reactive antibody >10%, or positive cross-match) received ATG (1.5 mg/kg) for 7 days (ATG7), and the remaining lower-risk group received ATG for 5 days (ATG5), all followed by calcineurin inhibitor, mycophenolate, and prednisone. Endomyocardial biopsies were performed based a standard protocol for up to 3 years after heart transplantation, and for suspected rejection.Of 253 heart transplant recipients, 87 received ATG5 and 166 ATG7. Absolute lymphocyte count <200 per microliter was achieved within 10 days in 88% of ATG5 and 86% of ATG7. Baseline creatinine was 1.3 ± 0.8 pre-transplantation, 1.8 ± 0.9 post-transplantation, and 1.0 ± 0.4 mg/dL at discharge (mean ± standard deviation [SD]; P < .001, compared with pre-transplantation). Of 3667 biopsies, 33 (0.90%) had ≥3A/2R cellular rejection (CR). Of 3599 biopsies, 16 (0.44%) had definite antibody-mediated rejection (AMR). At 5 years, freedom from ≥3A/2R CR (94% ± 2.8% vs 83% ± 7.7%; P = .31) and freedom from AMR (95% ± 2.4% vs 90% ± 6.4%; P = .98) were similar between ATG5 and ATG7, respectively. Survival for ATG5 and ATG7 was comparable at one year (94% ± 2.5% vs 93% ± 2.0%), and at 8 years (61% ± 6.9% and 61% ± 4.7%; P = .88). At 5 years, ATG5 and ATG7 were similar in freedom from cytomegalovirus (CMV) infection (92.3% vs 94.3%; P = not significant [NS]), freedom from pneumonia (83.8% vs 82.1%; P = NS), and in rate of malignancy (excluding skin cancer; 8.0% vs 6.0%; P = NS).ATG induction therapy (prospectively dose-adjusted for immunologic risk) in low- and high-risk patients results in excellent and equivalent short- and long-term survival rates, with a low incidence of CR and AMR. The use of ATG does not increase rates of CMV infection with appropriate prophylaxis. ATG may benefit renal function by delaying calcineurin inhibitor exposure, and may have a role in the prevention of AMR." @default.
• W2068240849 created "2016-06-24" @default.
• W2068240849 creator A5003282347 @default.
• W2068240849 creator A5003714120 @default.
• W2068240849 creator A5007033843 @default.
• W2068240849 creator A5020746104 @default.
• W2068240849 creator A5022095301 @default.
• W2068240849 creator A5048644691 @default.
• W2068240849 creator A5057486633 @default.
• W2068240849 creator A5057510155 @default.
• W2068240849 creator A5064412838 @default.
• W2068240849 creator A5073318290 @default.
• W2068240849 creator A5075691220 @default.
• W2068240849 creator A5080090853 @default.
• W2068240849 date "2013-07-01" @default.
• W2068240849 modified "2023-10-04" @default.
• W2068240849 title "Antithymocyte Globulin Induction Therapy Adjusted for Immunologic Risk After Heart Transplantation" @default.
• W2068240849 cites W15082559 @default.
• W2068240849 cites W1964874058 @default.
• W2068240849 cites W1965342731 @default.
• W2068240849 cites W1976230377 @default.
• W2068240849 cites W1982528317 @default.
• W2068240849 cites W1990136050 @default.
• W2068240849 cites W1991664893 @default.
• W2068240849 cites W1995622690 @default.
• W2068240849 cites W2019651965 @default.
• W2068240849 cites W2027447956 @default.
• W2068240849 cites W2038182050 @default.
• W2068240849 cites W2042257572 @default.
• W2068240849 cites W2043250502 @default.
• W2068240849 cites W2045224955 @default.
• W2068240849 cites W2060869747 @default.
• W2068240849 cites W2063030105 @default.
• W2068240849 cites W2083340153 @default.
• W2068240849 cites W2093231622 @default.
• W2068240849 cites W2103383683 @default.
• W2068240849 cites W2112400245 @default.
• W2068240849 cites W2117815681 @default.
• W2068240849 cites W2132220648 @default.
• W2068240849 cites W2158984215 @default.
• W2068240849 cites W2168499787 @default.
• W2068240849 cites W2168540650 @default.
• W2068240849 cites W2341259055 @default.
• W2068240849 cites W4231511662 @default.
• W2068240849 cites W4250483374 @default.
• W2068240849 doi "https://doi.org/10.1016/j.transproceed.2013.02.114" @default.
• W2068240849 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23953554" @default.
• W2068240849 hasPublicationYear "2013" @default.
• W2068240849 type Work @default.
• W2068240849 sameAs 2068240849 @default.
• W2068240849 citedByCount "18" @default.
• W2068240849 countsByYear W20682408492014 @default.
• W2068240849 countsByYear W20682408492015 @default.
• W2068240849 countsByYear W20682408492016 @default.
• W2068240849 countsByYear W20682408492017 @default.
• W2068240849 countsByYear W20682408492018 @default.
• W2068240849 countsByYear W20682408492019 @default.
• W2068240849 countsByYear W20682408492020 @default.
• W2068240849 countsByYear W20682408492023 @default.
• W2068240849 crossrefType "journal-article" @default.
• W2068240849 hasAuthorship W2068240849A5003282347 @default.
• W2068240849 hasAuthorship W2068240849A5003714120 @default.
• W2068240849 hasAuthorship W2068240849A5007033843 @default.
• W2068240849 hasAuthorship W2068240849A5020746104 @default.
• W2068240849 hasAuthorship W2068240849A5022095301 @default.
• W2068240849 hasAuthorship W2068240849A5048644691 @default.
• W2068240849 hasAuthorship W2068240849A5057486633 @default.
• W2068240849 hasAuthorship W2068240849A5057510155 @default.
• W2068240849 hasAuthorship W2068240849A5064412838 @default.
• W2068240849 hasAuthorship W2068240849A5073318290 @default.
• W2068240849 hasAuthorship W2068240849A5075691220 @default.
• W2068240849 hasAuthorship W2068240849A5080090853 @default.
• W2068240849 hasConcept C126322002 @default.
• W2068240849 hasConcept C128057223 @default.
• W2068240849 hasConcept C141071460 @default.
• W2068240849 hasConcept C2776694085 @default.
• W2068240849 hasConcept C2776755627 @default.
• W2068240849 hasConcept C2778720950 @default.
• W2068240849 hasConcept C2778849806 @default.
• W2068240849 hasConcept C2780252810 @default.
• W2068240849 hasConcept C2780303639 @default.
• W2068240849 hasConcept C2780306776 @default.
• W2068240849 hasConcept C2911091166 @default.
• W2068240849 hasConcept C64518967 @default.
• W2068240849 hasConcept C71924100 @default.
• W2068240849 hasConcept C90924648 @default.
• W2068240849 hasConceptScore W2068240849C126322002 @default.
• W2068240849 hasConceptScore W2068240849C128057223 @default.
• W2068240849 hasConceptScore W2068240849C141071460 @default.
• W2068240849 hasConceptScore W2068240849C2776694085 @default.
• W2068240849 hasConceptScore W2068240849C2776755627 @default.
• W2068240849 hasConceptScore W2068240849C2778720950 @default.
• W2068240849 hasConceptScore W2068240849C2778849806 @default.
• W2068240849 hasConceptScore W2068240849C2780252810 @default.
• W2068240849 hasConceptScore W2068240849C2780303639 @default.
• W2068240849 hasConceptScore W2068240849C2780306776 @default.
• W2068240849 hasConceptScore W2068240849C2911091166 @default.
• W2068240849 hasConceptScore W2068240849C64518967 @default.

• next